Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523 · see citing works

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Keech, C., Albert, G., Cho, I., Robertson, A., Reed, P., Neal, S., Plested, J. S., Zhu, M., Cloney-Clark, S., Zhou, H., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2026920 · Cited by 1,156 · see citing works

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine

Wu, K., Werner, A. P., Koch, M., Choi, A., Narayanan, E., Stewart-Jones, G. B. E., Colpitts, T., Bennett, H., Boyoglu-Barnum, S., Shi, W., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2102179 · Cited by 409 · see citing works

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines

Shen, X., Tang, H., McDanal, C., Wagh, K., Fischer, W., Theiler, J., Yoon, H., Li, D., Haynes, B. F., Sanders, K. O., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.03.002 · Cited by 378 · see citing works

Emergence of a Novel SARS-CoV-2 Variant in Southern California

Zhang, W., Davis, B. D., Chen, S. S., Sincuir Martinez, J. M., Plummer, J. T., & Vail, E. (2021) · JAMA · doi:10.1001/jama.2021.1612 · Cited by 371 · see citing works

Emergence of a novel SARS-CoV-2 strain in Southern California, USAPreprint

Zhang, W.-J., Davis, B. D., Chen, S. S., et al. (2021) · medRxiv · doi:10.1101/2021.01.18.21249786 · Cited by 67 · see citing works

Mechanisms of SARS-CoV-2 entry into cells

Jackson, C. B., Farzan, M., Chen, B., & Choe, H. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00418-x · Cited by 3,082 · see citing works

The biological and clinical significance of emerging SARS-CoV-2 variants

Tao, K., Tzou, P. L., Nouhin, J., Gupta, R. K., de Oliveira, T., Kosakovsky Pond, S. L., Fera, D., & Shafer, R. W. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00408-x · Cited by 1,009 · see citing works

Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review

Fiolet, T., Kherabi, Y., MacDonald, C.-J., Ghosn, J., & Peiffer-Smadja, N. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.10.005 · Cited by 911 · see citing works

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis

Cromer, D., Steain, M., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Kent, S. J., Triccas, J. A., Khoury, D. S., & Davenport, M. P. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00267-6 · Cited by 590 · see citing works

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

Pegu, A., O’Connell, S. E., Schmidt, S. D., O’Dell, S., Talana, C. A., Lai, L., Albert, J., Anderson, E., Bennett, H., Corbett, K. S., et al. (2021) · Science · doi:10.1126/science.abj4176 · Cited by 527 · see citing works

SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact

Lipsitch, M., Krammer, F., Regev‐Yochay, G., Lustig, Y., & Balicer, R. D. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00662-4 · Cited by 340 · see citing works

Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2

Afkhami, S., D’Agostino, M. R., Zhang, A., Stacey, H. D., Marzok, A., Kang, A., Singh, R., Bavananthasivam, J., Ye, G., Luo, X., et al. (2022) · Cell · doi:10.1016/j.cell.2022.02.005 · Cited by 307 · see citing works

Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates

Corbett, K. S., Nason, M. C., Flach, B., Gagne, M., O’Connell, S., Johnston, T. S., Shah, S. N., Edara, V. V., Floyd, K., Lai, L., et al. (2021) · Science · doi:10.1126/science.abj0299 · Cited by 286 · see citing works

Immunological memory to SARS‐CoV ‐2 infection and COVID ‐19 vaccines

Sette, A., & Crotty, S. (2022) · Immunological Reviews · doi:10.1111/imr.13089 · Cited by 266 · see citing works

Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individualsPreprint

Planas, D., Veyer, D. L., Baidaliuk, A., Staropoli, I., Guivel‐Benhassine, F., Rajah, M. M., Planchais, C., Porrot, F., Robillard, N., Puech, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.26.445838 · Cited by 272 · see citing works

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains

Chen, R. E., Winkler, E. S., Case, J. B., Aziati, I. D., Bricker, T. L., Joshi, A., Darling, T. L., Ying, B., Errico, J. M., Shrihari, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03720-y · Cited by 209 · see citing works

Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes

Tada, T., Dcosta, B. M., Samanovic, M. I., Herati, R. S., Cornelius, A. R., Zhou, H., Vaill, A., Kazmierski, W., Mulligan, M. J., & Landau, N. R. (2021) · mBio · doi:10.1128/mbio.00696-21 · Cited by 152 · see citing works

Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2

Xu, K., Gao, P., Liu, S., Lu, S.-Y., Lei, W.-W., Zheng, T., Liu, X.-Y., Xie, Y.-F., Zhao, Z.-N., Guo, S.-X., et al. (2022) · Cell · doi:10.1016/j.cell.2022.04.029 · Cited by 140 · see citing works

Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel

Lustig, Y., Zuckerman, N. S., Nemet, I., Atari, N., Kliker, L., Regev‐Yochay, G., Sapir, E., Mor, O., Alroy‐Preis, S., Mendelson, E., et al. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.26.2100557 · Cited by 143 · see citing works

SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment

Li, D., Sempowski, G. D., Saunders, K. O., Acharya, P., & Haynes, B. F. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042420-113838 · Cited by 132 · see citing works

Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination

Gorman, M. J., Patel, N., Guebre‐Xabier, M., Zhu, A. L., Atyeo, C. G., Pullen, K. M., Loos, C., Goez-Gazi, Y., Carrion, R., Tian, J.-H., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100405 · Cited by 121 · see citing works

The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines

Mohammadi, M., Shayestehpour, M., & Mirzaei, H. (2021) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2021.101606 · Cited by 131 · see citing works

An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice

Nanishi, E., Borriello, F., O’Meara, T. R., McGrath, M. E., Saito, Y., Haupt, R. E., Seo, H., van Haren, S. D., Cavazzoni, C. B., Brook, B., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abj5305 · Cited by 122 · see citing works

Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia

Aggarwal, A., Stella, A. O., Walker, G. J., Akerman, A., Esneau, C., Milogiannakis, V., Burnett, D. L., McAllery, S., Silva, M. R., Lu, Y., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01135-7 · Cited by 121 · see citing works

Vaccination reduces need for emergency care in breakthrough COVID-19 infections: A multicenter cohort study

Bahl, A., Johnson, S., Maine, G. N., Garcia, M. H., Nimmagadda, S., Qu, L., & Chen, N. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100065 · Cited by 115 · see citing works

A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses

Sun, W., Liu, Y., Amanat, F., González‐Domínguez, I., McCroskery, S., Slamanig, S., Coughlan, L., Rosado, V. C., Lemus, N., Jangra, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26499-y · Cited by 112 · see citing works

Current Developments and Challenges of mRNA Vaccines

Chen, J., Chen, J., & Xu, Q. (2022) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-110220-031722 · Cited by 106 · see citing works

The global epidemic of SARS‐CoV‐2 variants and their mutational immune escape

Tian, D., Sun, Y., Zhou, J., & Ye, Q. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27376 · Cited by 101 · see citing works

Possible Link between Higher Transmissibility of Alpha, Kappa and Delta Variants of SARS-CoV-2 and Increased Structural Stability of Its Spike Protein and hACE2 Affinity

Kumar, V., Singh, J., Hasnain, S. E., & Sundar, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179131 · Cited by 94 · see citing works

A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope

VanBlargan, L. A., Adams, L., Liu, Z.-M., Chen, R. E., Gilchuk, P., Raju, S., Smith, B. K., Zhao, H.-Y., Case, J., Winkler, E. S., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.08.016 · Cited by 95 · see citing works

Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs

Bekliz, M., Adea, K., Vetter, P., Eberhardt, C. S., Hosszu-Fellous, K., Vu, D., Puhach, O., Essaidi-Laziosi, M., Waldvogel‐Abramowski, S., Stephan, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31556-1 · Cited by 91 · see citing works

Persistence of neutralizing antibodies a year after SARS‐CoV‐2 infection in humans

Haveri, A., Ekström, N., Solastie, A., Virta, C., Österlund, P., Isosaari, E., Nohynek, H., PALMU, A. A. I., & Melin, M. M. (2021) · European Journal of Immunology · doi:10.1002/eji.202149535 · Cited by 85 · see citing works

SARS-CoV-2 new variants: Characteristic features and impact on the efficacy of different vaccines

Khan, A., Khan, T., Ali, S., Aftab, S., Wang, Y., Wang, Q., Khan, M., Suleman, M., Ali, S., Heng, W., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112176 · Cited by 75 · see citing works

Heterogeneous Infectivity and Pathogenesis of SARS-CoV-2 Variants Beta, Delta and Omicron in Transgenic K18-hACE2 and Wildtype Mice

Tarrés-Freixas, F., Trinité, B., Pons-Grífols, A., Romero‐Durana, M., Riveira‐Muñoz, E., Ávila‐Nieto, C., Pérez, M., García-Vidal, E., Perez‐Zsolt, D., Muñoz‐Basagoiti, J., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.840757 · Cited by 67 · see citing works

A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera

Seephetdee, C., Bhukhai, K., Buasri, N., Leelukkanaveera, P., Lerdwattanasombat, P., Manopwisedjaroen, S., Phueakphud, N., Kuhaudomlarp, S., Olmedillas, E., Saphire, E. O., et al. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105370 · Cited by 70 · see citing works

Potency of BNT162b2 and mRNA‐1273 vaccine‐induced neutralizing antibodies against severe acute respiratory syndrome‐CoV‐2 variants of concern: A systematic review of in vitro studies

Noori, M., Nejadghaderi, S. A., Arshi, S., Carson‐Chahhoud, K., Ansarin, K., Kolahi, A., & Safiri, S. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2277 · Cited by 64 · see citing works

SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence

Tatsi, E., Filippatos, F., & Michos, A. G. (2021) · Epidemiology and Infection · doi:10.1017/s0950268821002430 · Cited by 63 · see citing works

Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients

Obéid, M., Suffiotti, M., Pellaton, C., Bouchaab, H., Cairoli, A., Salvadé, V., Stevenel, C., Hottinger, R., Pythoud, C., Coutechier, L., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.0446 · Cited by 63 · see citing works

Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial

Madhi, S. A., Moodley, D., Hanley, S., Archary, M., Hoosain, Z., Lalloo, U., Louw, C. E., Fairlie, L., Fouche, L. F., Masilela, M. S. L., et al. (2022) · The Lancet HIV · doi:10.1016/s2352-3018(22)00041-8 · Cited by 61 · see citing works

The ins and outs of SARS-CoV-2 variants of concern (VOCs)

Salehi-Vaziri, ‪., Fazlalipour, M., Khorrami, S. M. S., Azadmanesh, K., Pouriayevali, M. H., Jalali, T., Shoja, Z., & Maleki, A. (2022) · Archives of Virology · doi:10.1007/s00705-022-05365-2 · Cited by 58 · see citing works

mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates

Corbett, K. S., Werner, A. P., Connell, S. O., Gagné, M., Lai, L., Moliva, J. I., Flynn, B. J., Choi, A., Koch, M., Foulds, K. E., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-01021-0 · Cited by 53 · see citing works

Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization

Zhang, L., Cui, Z.-M., Li, Q.-Q., Wang, B., Yu, Y.-L., Wu, J.-J., Nie, J.-H., Ding, R.-X., Wang, H.-X., Zhang, Y., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02728-4 · Cited by 52 · see citing works

Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial

Pitisuttithum, P., Luvira, V., Lawpoolsri, S., Muangnoicharoen, S., Kamolratanakul, S., Sivakorn, C., Narakorn, P., Surichan, S., Prangpratanporn, S., Puksuriwong, S., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101323 · Cited by 57 · see citing works

The way of SARS-CoV-2 vaccine development: success and challenges

Dong, Y., Dai, T., Wang, B., Zhang, L., Zeng, L., Huang, J., Yan, H., Zhang, L., & Zhou, F. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00796-w · Cited by 53 · see citing works

SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines

Singh, D. D., Parveen, A., & Yadav, D. K. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.777212 · Cited by 51 · see citing works

High-affinity, neutralizing antibodies to SARS-CoV-2 can be made without T follicular helper cells

Chen, J., Chow, R. D.-W., Song, E., Mao, T., Israelow, B., Kamath, K., Bozekowski, J. D., Haynes, W. A., Filler, R. B., Menasché, B. L., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abl5652 · Cited by 52 · see citing works

Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants

Ghimire, D., Han, Y., & Lu, M. (2022) · Viruses · doi:10.3390/v14061255 · Cited by 43 · see citing works

Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variantsPreprint

Pegu, A., O’Connell, S. E., Schmidt, S. D., O'Dell, S. J., Talana, C. A., Lai, L., Albert, J., Anderson, E. J., Bennett, H., Corbett, K. S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.13.444010 · Cited by 50 · see citing works

Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021

Xu, K., Dai, L., & Gao, G. F. (2021) · International Immunology · doi:10.1093/intimm/dxab061 · Cited by 48 · see citing works

Variants of Concern Are Overrepresented Among Postvaccination Breakthrough Infections of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Washington State

McEwen, A. E., Cohen, S., Bryson‐Cahn, C., Liu, C., Pergam, S. A., Lynch, J. B., Schippers, A., Strand, K., Whimbey, E. E., Mani, N. S., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab581 · Cited by 48 · see citing works

SARS-CoV-2 E484K Mutation Narrative Review: Epidemiology, Immune Escape, Clinical Implications, and Future Considerations

Yang, W.-T., Huang, W.-H., Liao, T.-L., Hsiao, T.-H., Chuang, H.-N., & Liu, P.-Y. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s344099 · Cited by 45 · see citing works

SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses

Carnell, G., Ciazynska, K. A., Wells, D. A., Xiong, X., Aguinam, E. T., McLaughlin, S. H., Mallery, D. L., Ebrahimi, S., Ceron‐Gutierrez, L., Asbach, B., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00203-21 · Cited by 45 · see citing works

Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview

Mehra, R., & Kepp, K. P. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00433 · Cited by 45 · see citing works

Emergence of a recurrent insertion in the N-terminal domain of the SARS-CoV-2 spike glycoprotein

Gerdol, M., Dishnica, K., & Giorgetti, A. (2022) · Virus Research · doi:10.1016/j.virusres.2022.198674 · Cited by 46 · see citing works

Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates

Corbett, K. S., Nason, M. C., Flach, B., Gagne, M., O’ Connell, S., Johnston, T. S., Shah, S. N., Edara, V. V., Floyd, K., Lai, L., et al. (2021) · doi:10.1101/2021.04.20.440647 · Cited by 43 · see citing works

Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H

Zeng, C., Evans, J. P., Faraone, J. N., Qu, P., Zheng, Y.-M., Saif, L., Oltz, E. M., Lozanski, G., Gumina, R. J., & Liu, S.-L. (2021) · mBio · doi:10.1128/mbio.02510-21 · Cited by 44 · see citing works

Evolution of the SARS-CoV-2 genome and emergence of variants of concern

Safari, I., & Elahi, E. (2021) · Archives of Virology · doi:10.1007/s00705-021-05295-5 · Cited by 41 · see citing works

COVID-19: From emerging variants to vaccination

Senevirathne, T. H., Wekking, D., Swain, J. W. R., Solinas, C., & Silva, P. D. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.11.005 · Cited by 42 · see citing works

SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents

García-Valtanen, P., Hope, C. M., Masavuli, M. G., Yeow, A. E. L., Balachandran, H., Mekonnen, Z. A., Al-Delfi, Z., Abayasingam, A., Agapiou, D., Stella, A. O., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100651 · Cited by 42 · see citing works

Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152Preprint

Yadav, P. D., Sapkal, G. N., Ella, R., Sahay, R. R., Nyayanit, D. A., Patil, D. Y., Deshpande, G. R., Shete, A. M., Gupta, N., Mohan, V., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.05.447177 · Cited by 39 · see citing works

Antigenic evolution of SARS coronavirus 2

Mykytyn, A. Z., Fouchier, R. A. M., & Haagmans, B. L. (2023) · Current Opinion in Virology · doi:10.1016/j.coviro.2023.101349 · Cited by 36 · see citing works

Nanomedicine for drug resistant pathogens and COVID-19 using mushroom nanocomposite inspired with bacteriocin – A review

Srinivash, M., Krishnamoorthi, R., Mahalingam, P. U., Malaikozhundan, B., Bharathakumar, S., Gurushankar, K., Dhanapal, K., Samy, K. K., & Perumal, A. B. (2023) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2023.110682 · Cited by 37 · see citing works

Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial

Bánki, Z., Mateus, J., Rössler, A., Schäfer, H., Bante, D., Riepler, L., Grifoni, A., Sette, A., Simon, V. R., Falkensammer, B., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104073 · Cited by 37 · see citing works

Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects

Lusvarghi, S., Wang, W., Herrup, R., Neerukonda, S., Vassell, R., Bentley, L., Eakin, A., Erlandson, K. J., & Weiss, C. (2021) · bioRxiv · doi:10.1128/jvi.01110-21 · Cited by 38 · see citing works

Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants

da Silva, S. J. R., de Lima, S. C., da Silva, R. C., Kohl, A., & Pena, L. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.836826 · Cited by 36 · see citing works

BNT162b2 vaccination enhances interferon-JAK-STAT-regulated antiviral programs in COVID-19 patients infected with the SARS-CoV-2 Beta variant

Knabl, L., Lee, H., Wieser, M., Mur, A., Zabernigg, A. F., Knabl, L., Rauch, S., Böck, M., Schumacher, J., Kaiser, N., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00083-x · Cited by 35 · see citing works

SARS-CoV-2 variant transition dynamics are associated with vaccination rates, number of co-circulating variants, and convalescent immunity

Beesley, L. J., Moran, K. R., Wagh, K., Castro, L. A., Theiler, J. P., Yoon, H., Fischer, W., Hengartner, N., Korber, B., & Valle, S. Y. D. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104534 · Cited by 34 · see citing works

A SARS‐CoV‐2 Neutralization Assay Using Single Molecule Arrays

Gilboa, T., Cohen, L., Cheng, C., Lazarovits, R., Uwamanzu‐Nna, A., Han, I., Griswold, K., Barry, N., Thompson, D. B., Kohman, R. E., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202110702 · Cited by 33 · see citing works

A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants

Weinstein, J. B., Bates, T. A., Leier, H. C., McBride, S. K., Barklis, E., & Tafesse, F. (2022) · iScience · doi:10.1016/j.isci.2022.103960 · Cited by 32 · see citing works

SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern

Hawman, D. W., Meade-White, K., Archer, J. F., Leventhal, S. S., Wilson, D., Shaia, C., Randall, S., Khandhar, A. P., Krieger, K., Hsiang, T.-Y., et al. (2022) · eLife · doi:10.7554/elife.75537 · Cited by 34 · see citing works

The Immune Response to SARS-CoV-2 and Variants of Concern

Torbati, E., Krause, K. L., & Ussher, J. E. (2021) · Viruses · doi:10.3390/v13101911 · Cited by 32 · see citing works

Modeling insights into SARS-CoV-2 respiratory tract infections prior to immune protection

Chen, A. J., Wessler, T., Daftari, K., Hinton, K. Y., Boucher, R. C., Pickles, R. J., Freeman, R., Lai, S. K., & Forest, M. G. (2022) · Biophysical Journal · doi:10.1016/j.bpj.2022.04.003 · Cited by 32 · see citing works

An in-depth in silico and immunoinformatics approach for designing a potential multi-epitope construct for the effective development of vaccine to combat against SARS-CoV-2 encompassing variants of concern and interest

Saba, A. A., Adiba, M., Saha, P., Hosen, M. I., Chakraborty, S., & Nabi, A. N. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104703 · Cited by 32 · see citing works

SARS CoV-2 Delta variant exhibits enhanced infectivity and a minor decrease in neutralization sensitivity to convalescent or post-vaccination sera

Kuzmina, A., Wattad, S., Khalaila, Y., Ottolenghi, A., Rosental, B., Engel, S., Rosenberg, E., & Taube, R. (2021) · iScience · doi:10.1016/j.isci.2021.103467 · Cited by 30 · see citing works

A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2

Yuan, Y., Zhang, X., Chen, R., Li, Y., Wu, B., Li, R., Zou, F., Ma, X., Wang, X., Chen, Q., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110256 · Cited by 31 · see citing works

Pseudotyped Vesicular Stomatitis Virus-Severe Acute Respiratory Syndrome-Coronavirus-2 Spike for the Study of Variants, Vaccines, and Therapeutics Against Coronavirus Disease 2019

Salazar–García, M., Acosta-Contreras, S., Martinez, G. R., Cruz‐Rangel, A., Flores-Alanis, A., Patiño‐López, G., & Luna-Pineda, V. M. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.817200 · Cited by 29 · see citing works

A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants

Zhang, J., Han, Z. B., Liang, Y., Zhang, X. F., Jin, Y. Q., Du, L. F., Shao, S., Wang, H., Hou, J. W., Xu, K., et al. (2022) · eLife · doi:10.7554/elife.78633 · Cited by 27 · see citing works

Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2

Castonguay, N., Zhang, W., & Langlois, M. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.676314 · Cited by 28 · see citing works

Isolation and characterization of SARS-CoV-2 Beta variant from UAE travelers

Yadav, P. D., Sarkale, P., Razdan, A., Gupta, N., Nyayanit, D. A., Sahay, R. R., Potdar, V. A., Patil, D. Y., Baradkar, S., Kumar, A., et al. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.12.011 · Cited by 28 · see citing works

Genomic Epidemiology of SARS-CoV-2 Divulge B.1, B.1.36, and B.1.1.7 as the Most Dominant Lineages in First, Second, and Third Wave of SARS-CoV-2 Infections in Pakistan

Basheer, A., & Zahoor, I. (2021) · Microorganisms · doi:10.3390/microorganisms9122609 · Cited by 28 · see citing works

Research progress on vaccine efficacy against SARS-CoV-2 variants of concern

Bian, L., Liu, J., Gao, F., Gao, Q., He, Q., Mao, Q., Wu, X., Xu, M., & Liang, Z. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2057161 · Cited by 29 · see citing works

Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters

Takamatsu, Y., Imai, M., Maeda, K., Nakajima, N., Higashi‐Kuwata, N., Iwatsuki‐Horimoto, K., Ito, M., Kiso, M., Maemura, T., Takeda, Y., et al. (2021) · Journal of Virology · doi:10.1128/jvi.01551-21 · Cited by 26 · see citing works

A review of the safety and efficacy of current COVID-19 vaccines

Huang, Z., Su, Y., Zhang, T., & Xia, N. (2022) · Frontiers of Medicine · doi:10.1007/s11684-021-0893-y · Cited by 27 · see citing works

COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants

Junker, D., Dulovic, A., Becker, M., Wagner, T. R., Kaiser, P. D., Traenkle, B., Kienzle, K., Bunk, S., Struemper, C., Haeberle, H., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-10987-2 · Cited by 23 · see citing works

Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infection

Khatamzas, E., Antwerpen, M. H., Rehn, A., Graf, A., Hellmuth, J. C., Hollaus, A., Mohr, A., Gaitzsch, E., Weiglein, T., Georgi, E., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32772-5 · Cited by 22 · see citing works

Quantifying the role of naturally- and vaccine-derived neutralizing antibodies as a correlate of protection against COVID-19 variantsPreprint

Cohen, J. A., Stuart, R. M., Rosenfeld, K., Lyons, H. M., White, M. T., Kerr, C. C., Klein, D. J., & Famulare, M. (2021) · medRxiv · doi:10.1101/2021.05.31.21258018 · Cited by 21 · see citing works

Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines

Zhang, Y., Ndzouboukou, J. B., Gan, M., Lin, X., & Fan, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.771242 · Cited by 21 · see citing works

Development of antibody resistance in emerging mutant strains of SARS CoV‐2: Impediment for COVID‐19 vaccines

Beeraka, N. M., Sukocheva, O. A., Lukina, E., Liu, J., & Fan, R. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2346 · Cited by 22 · see citing works

Analysis of the Protective Efficacy of Approved COVID-19 Vaccines Against Various Mutants

Li, C., Guo, Y., Fang, Z., Zhang, H., Zhang, Y., & Chen, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.804945 · Cited by 23 · see citing works

Aerosol Transport Modeling: The Key Link Between Lung Infections of Individuals and Populations

Darquenne, C., Borojeni, A. A. T., Colebank, M. J., Forest, M. G., Madas, B. G., Tawhai, M. H., & Jiang, Y. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.923945 · Cited by 23 · see citing works

Controlling long-term SARS-CoV-2 infections can slow viral evolution and reduce the risk of treatment failure

Egeren, D. V., Novokhodko, A., Stoddard, M., Tran, U., Zetter, B. R., Rogers, M. S., Joseph‐McCarthy, D., & Chakravarty, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-02148-8 · Cited by 20 · see citing works

“Original antigenic sin”: A potential threat beyond the development of booster vaccination against novel SARS-CoV-2 variants

Noori, M., Nejadghaderi, S. A., & Rezaei, N. (2021) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.199 · Cited by 22 · see citing works

Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concernPreprint

Fiolet, T., Kherabi, Y., MacDonald, C. J., Ghosn, J., & Peiffer‐Smadja, N. (2021) · doi:10.31219/osf.io/z4x7t · Cited by 22 · see citing works

Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination

Chen, Y.-X., Zhu, L.-G., Huang, W.-J., Tong, X., Wu, H., Tao, Y., Tong, B., Huang, H., Chen, J., Zhao, X.-A., et al. (2021) · Emerging Microbes and Infections · doi:10.1080/22221751.2021.1942227 · Cited by 21 · see citing works

Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy

Spiliopoulou, P., van Rensburg, H. J. J., Avery, L. M., Kulasingam, V., Razak, A. R. A., Bedard, P. L., Hansen, A. R., Chruscinski, A. J., Wang, B., Kulikova, M., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-022-05548-4 · Cited by 21 · see citing works

Variantes de SARS-CoV-2, una historia todavía inacabada

Pérez-Abeledo, M., & Moreno, J. C. S. (2021) · Vacunas · doi:10.1016/j.vacun.2021.06.003 · Cited by 20 · see citing works

Geographical prevalence of SARS-CoV-2 variants, August 2020 to July 2021

Chan, W. S., Lam, Y. M., Law, J. H. Y., Chan, T. L., Ma, E. S. K., & Tang, B. S. F. (2022) · Scientific Reports · doi:10.1038/s41598-022-08684-1 · Cited by 19 · see citing works

Rational Development of a Polysaccharide–Protein‐Conjugated Nanoparticle Vaccine Against SARS‐CoV‐2 Variants and Streptococcus pneumoniae

Deng, Y., Li, J., Sun, C., Chi, H., Luo, D., Wang, R., Qiu, H., Zhang, Y., Wu, M. L., Zhang, X., et al. (2022) · Advanced Materials · doi:10.1002/adma.202200443 · Cited by 19 · see citing works

A broadly reactive antibody targeting the N-terminal domain of SARS-CoV-2 spike confers Fc-mediated protection

Adams, L., VanBlargan, L. A., Liu, Z.-M., Gilchuk, P., Zhao, H.-Y., Chen, R. E., Raju, S., Chong, Z.-L., Whitener, B. M., Shrihari, S., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101305 · Cited by 16 · see citing works

Probing the formation, structure and free energy relationships of M protein dimers of SARS-CoV-2

Cao, Y.-P., Yang, R.-R., Wang, W., Jiang, S., Yang, C., Liu, N.-B., Dai, H.-J., Lee, I., Meng, X.-F., & Yuan, Z. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.01.007 · Cited by 16 · see citing works

SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants

Khamees, A., Bani-Issa, J., Zoubi, M. S. A., Qasem, T., AbuAlarjah, M. I., Alawadin, S. A., Al-Shami, K., Hussein, F. E., Hussein, E. I., Bashayreh, I. H., et al. (2022) · Pathogens · doi:10.3390/pathogens11020275 · Cited by 14 · see citing works

Original Hosts, Clinical Features, Transmission Routes, and Vaccine Development for Coronavirus Disease (COVID-19)

Wu, T., Kang, S., Peng, W., Zuo, C., Zhu, Y., Pan, L., Fu, K., You, Y., Yang, X., Luo, X., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.702066 · Cited by 19 · see citing works

Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants

Anichini, G., Terrosi, C., Savellini, G. G., Gandolfo, C., Franchi, F., & Cusi, M. G. (2021) · Vaccines · doi:10.3390/vaccines9050517 · Cited by 18 · see citing works

Antibody neutralization to SARS-CoV-2 and variants after 1 year in Wuhan, China

Liu, Q., Xiong, Q., Mei, F., Ma, C., Zhang, Z., Hu, B., Xu, J., Jiang, Y., Zhan, F., Zhou, S., et al. (2021) · The Innovation · doi:10.1016/j.xinn.2021.100181 · Cited by 18 · see citing works

Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases

Iyer, S., Yadav, R. T., Agarwal, S., Tripathi, S., & Agarwal, R. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00123-21 · Cited by 29 · see citing works

"Cross-Reactivity of Neutralizing Antibodies Against SARS-CoV-2 in Patients Infected by Various Clades (S, L, V, GR, G, GH and GV)"

Kim, E. (2023) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2023.52.008186

BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants

Liu, Y., Liu, J., Xia, H., Zhang, X., Zou, J., Fontes-Garfias, C. R., Weaver, S. C., Swanson, K. A., Cai, H., Sarkar, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2106083 · Cited by 90 · see citing works

SARS-CoV-2 Spike Pseudoviruses: A Useful Tool to Study Virus Entry and Address Emerging Neutralization Escape Phenotypes

Kalkeri, R., Cai, Z., Lin, S., Farmer, J., Kuzmichev, Y. V., & Koide, F. (2021) · Microorganisms · doi:10.3390/microorganisms9081744 · Cited by 25 · see citing works

Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization

Wang, G., Wang, Z.-Y., Duan, L., Meng, Q.-C., Jiang, M.-D., Cao, J., Lin, Y., Zhu, K.-L., Cao, W., & Ma, M. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2103022 · Cited by 160 · see citing works

Additional file 1 of Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2

Chiang, H.-L., Liang, K.-H., Lu, R.-M., Kuo, T.-W., Lin, Y., & Wu, H.-C. (2023) · Figshare · doi:10.6084/m9.figshare.23812506